GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Steminent Biotherapeutics Inc (ROCO:7729) » Definitions » EV-to-Revenue

Steminent Biotherapeutics (ROCO:7729) EV-to-Revenue : (As of May. 24, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Steminent Biotherapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Steminent Biotherapeutics's enterprise value is NT$1,098.14 Mil. Steminent Biotherapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was NT$0.00 Mil. Therefore, Steminent Biotherapeutics's EV-to-Revenue for today is .

The historical rank and industry rank for Steminent Biotherapeutics's EV-to-Revenue or its related term are showing as below:

During the past 5 years, the highest EV-to-Revenue of Steminent Biotherapeutics was 1618.85. The lowest was 756.13. And the median was 988.86.

ROCO:7729's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.16
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-05-24), Steminent Biotherapeutics's stock price is NT$22.25. Steminent Biotherapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was NT$0.00. Therefore, Steminent Biotherapeutics's PS Ratio for today is .


Steminent Biotherapeutics EV-to-Revenue Historical Data

The historical data trend for Steminent Biotherapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Steminent Biotherapeutics EV-to-Revenue Chart

Steminent Biotherapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-Revenue
- - - - -

Steminent Biotherapeutics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-Revenue Get a 7-Day Free Trial - - - - -

Competitive Comparison of Steminent Biotherapeutics's EV-to-Revenue

For the Biotechnology subindustry, Steminent Biotherapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Steminent Biotherapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Steminent Biotherapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Steminent Biotherapeutics's EV-to-Revenue falls into.


;
;

Steminent Biotherapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Steminent Biotherapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=1098.139/0
=

Steminent Biotherapeutics's current Enterprise Value is NT$1,098.14 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Steminent Biotherapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was NT$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Steminent Biotherapeutics  (ROCO:7729) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Steminent Biotherapeutics's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=22.25/0
=

Steminent Biotherapeutics's share price for today is NT$22.25.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2024 was NT$0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Steminent Biotherapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Steminent Biotherapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Steminent Biotherapeutics Business Description

Traded in Other Exchanges
N/A
Address
No.16,Wenhu Street, Neihu District, Taipei, TWN, 11445
Steminent Biotherapeutics Inc is a international stem cell biopharmaceutical company which has stable and efficient stem cell platform technology, aiming to develop live cell drugs to treat degenerative diseases as well as acute and life-threatening diseases. With its Stemchymal which is proprietary technology platform generating the standardized, clinical grade, allogeneic stem cells isolated from human adipose tissue. It is operated in strict compliance to regulations of Taiwan, the US, and Japan.

Steminent Biotherapeutics Headlines

No Headlines